ArticleSmall science2024
Biomimetic Functional Nanocomplexes for Photothermal Cancer Chemoimmunotheranostics.
Article in Small science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Nanoparticle delivery of Chinese medicine monomers for remodeling the colorectal cancer immune microenvironment.Discover nano · 2026Review
- Protein-Based Nanomaterials for Cancer Therapy: A Comparative and Translational Perspective.Pharmaceutics · 2026Review
- Multifunctional Magnetic Ionic Liquid-Carbon Nanohorn Complexes for Targeted Cancer Theranostics.Small science · 2025Article
- Visualization of Stress Fiber Formation Induced by Photodynamic Therapy with Porphylipoprotein.Nanomaterials (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study presents a novel multimodal cancer theranostic platform developed using tumor cell-coated biomimetic carbon nanohorn (CNH) complexes that encapsulate the anticancer drug paclitaxel (PTX). This platform combines photothermal therapy, chemotherapy, and immunotherapy to fight against malignant colorectal cancer. These engineered nanocomplexes are designed to deliver sufficient PTX molecules into a targeted solid tumor in a light-controllable manner while inducing significant photothermal and antitumor immune responses. The outstanding photothermal conversion property of the CNHs under near-infrared light enables effective cancer cell ablation and awakening of cytotoxic immune responses. Tumor cell membrane-coated CNHs show improved water dispersibility, immune evasion, and targeting capabilities alongside enhanced immune activation against tumors. The efficacy of the biomimetic functional CNH nanocomplexes is demonstrated through excellent tumor-targeting, controlled drug-releasing behavior, and induction of cancer cell death, contributing to a robust antitumor response. This study provides a promising approach to cancer treatment by integrating multiple therapeutic modalities into a single platform, potentially enhancing treatment efficacy to combat intractable cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.